02403nam a22004811i 4500 000706474 CaToSAGE 20240202172226.0 20230109140345.7 m o d cr un||||||||| 230109s2020 enk fo 000 0 eng d NEZPRACOVANÝ IMPORT 9781529619843 : No price (ebook) (OCoLC)1362531007 CaToSAGE eng rda pn CaToSAGE UtOrBLW HD45 .S24 2020 658.514 Sahay, Arvind, author. Lupin : discovery research / Arvind Sahay, Tara Tiwari, Raj Kamboj, Pelle Venkata, Sharad Sharma. London : Indian Institute of Management, Ahmedabad, 2020. 1 online resource. text txt rdacontent computer c rdamedia online resource cr rdacarrier SAGE business cases Lupin, an India-based pharma firm, started its Novel Drug Discovery and Development (NDDD) division in 2010, for which it built infrastructure from scratch. In 2018, Lupin's NDDD successfully licensed MALT1 inhibitors to AbbVie, a multinational pharma firm, for a down payment of USD 30 million and progressive payments of USD 947 million over 10 years. This was the first success for this division. Going forward, Lupin had two programs in the clinical development stage. It now had to decide whether to go ahead with the clinical trials or license these two molecules as well.The case revolves around the organizational system and processes (industry-specific, company-specific) and market conditions that influence innovation and commercialisation of an innovation in the organization. Description based on XML content. elektronické knihy fd186907 czenas electronic books eczenas Technological innovations Case studies. Marketing Management Case studies. Tiwari, Tara, author. Kamboj, Raj, author. Vēṅkaṭa Subbārāvu, Paḷḷe, author. Sharma, Sharad (Sharad K.), author. SAGE business cases. SAGE Knowledge https://sk.sagepub.com/cases/lupin-discovery-research Plný text SBC EB NEPOSILAT EB